PAF formation by human gastrointestinal mucosa/submucosa in-vitro: release by ricinoleic acid, and inhibition by 5-aminosalicylic acid.
Human isolated gastrointestinal mucosa/submucosa incubated with ricinoleic acid (12.5-100 micrograms mL-1) or the calcium ionophore A23187 (10 micrograms mL-1) released platelet-activating factor (PAF) as determined by a scintillation proximity assay after extraction and purification. 5-Aminosalicylic acid (25-100 micrograms mL-1) inhibited PAF release by ricinoleic acid in a concentration-dependent manner, and 50 micrograms mL-1 reduced the effect of A23187. We suggest that PAF may play a role in the laxation and mucosal damage by ricinoleic acid released from castor oil.
Capasso
F
F
Department of Surgery, King's College School of Medicine and Dentistry, Rayne Institute, London, UK.
Tavares
I A
IA
Bennett
A
A
D000636:Aminosalicylic Acids / Q000494:pharmacology*; D000001:Calcimycin / Q000494:pharmacology; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism*; D019804:Mesalamine; D010972:Platelet Activating Factor / Q000096:biosynthesis*; D012277:Ricinoleic Acids / Q000494:pharmacology*
D000636:Aminosalicylic Acids; D010972:Platelet Activating Factor; D012277:Ricinoleic Acids; D000001:Calcimycin; D019804:Mesalamine; C030521:ricinoleic acid